NCT07070440

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

A Phase 1/2, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Dizal Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	DZD6008	DZD6008 was administered orally at 40/60/90 mg QD.
DRUG	Pemetrexed	Pemetrexed 500 mg/m2, every 3 weeks, intravenous infusion.
DRUG	Carboplatin	Carboplatin AUC 5 mg/mL/min, every 3 weeks, intravenous infusion.
DRUG	Docetaxel	Docetaxel 75 mg/m2, every 3 weeks, intravenous infusion.

Timeline

• Start date: 2025-07-16
• Primary completion: 2027-06-01
• Completion: 2028-12-01
• First posted: 2025-07-17
• Last updated: 2025-08-29

Locations

1 site across 1 country: China